{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:10:58Z","timestamp":1793797858520,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that sortilin-related receptor 1 (SORLA;\n                    <jats:italic>SORL1<\/jats:italic>\n                    ) co-precipitates with HER2 in cancer cells and regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. SORLA protein levels in cancer cell lines and bladder cancers correlates with HER2 levels. Depletion of SORLA triggers HER2 targeting to late endosomal\/lysosomal compartments and impairs HER2-driven signalling and in vivo tumour growth. SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These findings reveal potentially important SORLA-dependent endosomal trafficking-linked vulnerabilities in HER2-driven cancers.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-10275-0","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:04:16Z","timestamp":1559023456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["SORLA regulates endosomal trafficking and oncogenic fitness of HER2"],"prefix":"10.1038","volume":"10","author":[{"given":"Mika","family":"Pietil\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranshu","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-3046","authenticated-orcid":false,"given":"Emilia","family":"Peuhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas Z.","family":"J\u00e4ntti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-2396","authenticated-orcid":false,"given":"Ilkka","family":"Paatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"N\u00e4rv\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Al-Akhrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Georgiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav M.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Padzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5265-5509","authenticated-orcid":false,"given":"Harri","family":"Sihto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Blomqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Taimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6295-6556","authenticated-orcid":false,"given":"Johanna","family":"Ivaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"10275_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"H Joensuu","year":"2006","unstructured":"Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809\u2013820 (2006).","journal-title":"N. Engl. J. Med."},{"key":"10275_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"10275_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224\u2013237 (2013).","journal-title":"Cancer Discov."},{"key":"10275_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1078-0432.CCR-05-0976","volume":"12","author":"JW Lee","year":"2006","unstructured":"Lee, J. W. et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin. Cancer Res. 12, 57\u201361 (2006).","journal-title":"Clin. Cancer Res."},{"key":"10275_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","volume":"65","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu, H. et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65, 1642\u20131646 (2005).","journal-title":"Cancer Res."},{"key":"10275_CR6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1091\/mbc.e02-09-0578","volume":"14","author":"DE Hammond","year":"2003","unstructured":"Hammond, D. E. et al. Endosomal dynamics of Met determine signaling output. Mol. Biol. Cell 14, 1346\u20131354 (2003).","journal-title":"Mol. Biol. Cell"},{"key":"10275_CR7","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1128\/MCB.22.20.7279-7290.2002","volume":"22","author":"Y Wang","year":"2002","unstructured":"Wang, Y., Pennock, S., Chen, X. & Wang, Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol. Cell. Biol. 22, 7279\u20137290 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"10275_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.devcel.2014.05.018","volume":"29","author":"G Muharram","year":"2014","unstructured":"Muharram, G. et al. Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev. Cell 29, 629\u2013630 (2014).","journal-title":"Dev. Cell"},{"key":"10275_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11942","volume":"7","author":"R Barrow-McGee","year":"2016","unstructured":"Barrow-McGee, R. et al. Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes. Nat. Commun. 7, 11942 (2016).","journal-title":"Nat. Commun."},{"key":"10275_CR10","doi-asserted-by":"publisher","first-page":"e58148","DOI":"10.1371\/journal.pone.0058148","volume":"8","author":"L Henriksen","year":"2013","unstructured":"Henriksen, L., Grandal, M. V., Knudsen, S. L., van Deurs, B. & Grovdal, L. M. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS ONE 8, e58148 (2013).","journal-title":"PLoS ONE"},{"key":"10275_CR11","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/emboj.2013.149","volume":"32","author":"S Sigismund","year":"2013","unstructured":"Sigismund, S. et al. Threshold-controlled ubiquitination of the EGFR directs receptor fate. EMBO J. 32, 2140\u20132157 (2013).","journal-title":"EMBO J."},{"key":"10275_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/membranes4030424","volume":"4","author":"V Bertelsen","year":"2014","unstructured":"Bertelsen, V. & Stang, E. The mysterious ways of ErbB2\/HER2 trafficking. Membranes (Basel) 4, 424\u2013446 (2014).","journal-title":"Membranes (Basel)"},{"key":"10275_CR13","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1074\/jbc.271.9.5251","volume":"271","author":"J Baulida","year":"1996","unstructured":"Baulida, J., Kraus, M. H., Alimandi, M., Di Fiore, P. P. & Carpenter, G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271, 5251\u20135257 (1996).","journal-title":"J. Biol. Chem."},{"key":"10275_CR14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cellsig.2007.12.021","volume":"20","author":"F Shen","year":"2008","unstructured":"Shen, F., Lin, Q., Childress, C. & Yang, W. Identification of the domain in ErbB2 that restricts ligand-induced degradation. Cell. Signal. 20, 779\u2013786 (2008).","journal-title":"Cell. Signal."},{"key":"10275_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrm2748","volume":"10","author":"A Sorkin","year":"2009","unstructured":"Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609\u2013622 (2009).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10275_CR16","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1091\/mbc.e05-05-0456","volume":"16","author":"C Haslekas","year":"2005","unstructured":"Haslekas, C. et al. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol. Biol. Cell 16, 5832\u20135842 (2005).","journal-title":"Mol. Biol. Cell"},{"key":"10275_CR17","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1091\/mbc.e03-08-0596","volume":"15","author":"AM Hommelgaard","year":"2004","unstructured":"Hommelgaard, A. M., Lerdrup, M. & van Deurs, B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol. Biol. Cell 15, 1557\u20131567 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"10275_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1158\/1541-7786.MCR-07-0191","volume":"6","author":"NM Pedersen","year":"2008","unstructured":"Pedersen, N. M., Madshus, I. H., Haslekas, C. & Stang, E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol. Cancer Res. 6, 491\u2013500 (2008).","journal-title":"Mol. Cancer Res."},{"key":"10275_CR19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/nsmb885","volume":"12","author":"W Xu","year":"2005","unstructured":"Xu, W. et al. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12, 120\u2013126 (2005).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10275_CR20","first-page":"39","volume":"63","author":"O Tikhomirov","year":"2003","unstructured":"Tikhomirov, O. & Carpenter, G. Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res. 63, 39\u201343 (2003).","journal-title":"Cancer Res."},{"key":"10275_CR21","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","volume":"15","author":"CD Austin","year":"2004","unstructured":"Austin, C. D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15, 5268\u20135282 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"10275_CR22","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.1038\/sj.onc.1203973","volume":"19","author":"D Harari","year":"2000","unstructured":"Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2\/HER2 action in breast cancer. Oncogene 19, 6102\u20136114 (2000).","journal-title":"Oncogene"},{"key":"10275_CR23","first-page":"1130","volume":"63","author":"BS Hendriks","year":"2003","unstructured":"Hendriks, B. S., Opresko, L. K., Wiley, H. S. & Lauffenburger, D. Coregulation of epidermal growth factor receptor\/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 63, 1130\u20131137 (2003).","journal-title":"Cancer Res."},{"key":"10275_CR24","doi-asserted-by":"publisher","first-page":"31379","DOI":"10.1074\/jbc.271.49.31379","volume":"271","author":"L Jacobsen","year":"1996","unstructured":"Jacobsen, L. et al. Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. J. Biol. Chem. 271, 31379\u201331383 (1996).","journal-title":"J. Biol. Chem."},{"key":"10275_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.4161\/cib.21433","volume":"5","author":"AW Fjorback","year":"2012","unstructured":"Fjorback, A. W. & Andersen, O. M. SorLA is a molecular link for retromer-dependent sorting of the Amyloid precursor protein. Commun. Integr. Biol. 5, 616\u2013619 (2012).","journal-title":"Commun. Integr. Biol."},{"key":"10275_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0014-5793(01)03299-9","volume":"511","author":"L Jacobsen","year":"2002","unstructured":"Jacobsen, L. et al. The sorLA cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA binding. FEBS Lett. 511, 155\u2013158 (2002).","journal-title":"FEBS Lett."},{"key":"10275_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/ng1943","volume":"39","author":"E Rogaeva","year":"2007","unstructured":"Rogaeva, E. et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39, 168\u2013177 (2007).","journal-title":"Nat. Genet."},{"key":"10275_CR28","doi-asserted-by":"publisher","first-page":"13461","DOI":"10.1073\/pnas.0503689102","volume":"102","author":"OM Andersen","year":"2005","unstructured":"Andersen, O. M. et al. Neuronal sorting protein-related receptor sorLA\/LR11 regulates processing of the amyloid precursor protein. Proc. Natl. Acad. Sci. USA 102, 13461\u201313466 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10275_CR29","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/bi052120v","volume":"45","author":"OM Andersen","year":"2006","unstructured":"Andersen, O. M. et al. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA\/LR11. Biochemistry 45, 2618\u20132628 (2006).","journal-title":"Biochemistry"},{"key":"10275_CR30","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1242\/jcs.072538","volume":"124","author":"SC Klinger","year":"2011","unstructured":"Klinger, S. C. et al. SorLA regulates the activity of lipoprotein lipase by intracellular trafficking. J. Cell. Sci. 124, 1095\u20131105 (2011).","journal-title":"J. Cell. Sci."},{"key":"10275_CR31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.neuroscience.2008.10.061","volume":"158","author":"R Spoelgen","year":"2009","unstructured":"Spoelgen, R. et al. Interaction of the apolipoprotein E receptors low density lipoprotein receptor-related protein and sorLA\/LR11. Neuroscience 158, 1460\u20131468 (2009).","journal-title":"Neuroscience"},{"key":"10275_CR32","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1172\/JCI84708","volume":"126","author":"V Schmidt","year":"2016","unstructured":"Schmidt, V. et al. SORLA facilitates insulin receptor signaling in adipocytes and exacerbates obesity. J. Clin. Invest. 126, 2706\u20132720 (2016).","journal-title":"J. Clin. Invest."},{"key":"10275_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9951","volume":"6","author":"AJ Whittle","year":"2015","unstructured":"Whittle, A. J. et al. Soluble LR11\/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. Nat. Commun. 6, 8951 (2015).","journal-title":"Nat. Commun."},{"key":"10275_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.4161\/cbt.29687","volume":"15","author":"M de Martino","year":"2014","unstructured":"de Martino, M. et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol. Ther. 15, 1239\u20131247 (2014).","journal-title":"Cancer Biol. Ther."},{"key":"10275_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0076-6879(08)03606-9","volume":"452","author":"CL Vazquez","year":"2009","unstructured":"Vazquez, C. L. & Colombo, M. I. Assays to assess autophagy induction and fusion of autophagic vacuoles with a degradative compartment, using monodansylcadaverine (MDC) and DQ-BSA. Methods Enzymol. 452, 85\u201395 (2009).","journal-title":"Methods Enzymol."},{"key":"10275_CR36","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2013.08.003","volume":"24","author":"NH Petersen","year":"2013","unstructured":"Petersen, N. H. et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell. 24, 379\u2013393 (2013).","journal-title":"Cancer Cell."},{"key":"10275_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ebiom.2016.06.013","volume":"9","author":"AM Ellegaard","year":"2016","unstructured":"Ellegaard, A. M. et al. Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine 9, 130\u2013139 (2016).","journal-title":"EBioMedicine"},{"key":"10275_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725\u2013731 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"10275_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan, M. et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastas-. Rev. 34, 157\u2013164 (2015).","journal-title":"Cancer Metastas-. Rev."},{"key":"10275_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","volume":"47","author":"J Zhao","year":"2015","unstructured":"Zhao, J. et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int. Urol. Nephrol. 47, 87\u201394 (2015).","journal-title":"Int. Urol. Nephrol."},{"key":"10275_CR41","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1242\/jcs.103440","volume":"125","author":"MN Seaman","year":"2012","unstructured":"Seaman, M. N. The retromer complex\u2014endosomal protein recycling and beyond. J. Cell. Sci. 125, 4693\u20134702 (2012).","journal-title":"J. Cell. Sci."},{"key":"10275_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung, M. et al. Caveloae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol. Cancer Ther. 17, 243\u2013253 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"10275_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07608-w","volume":"9","author":"PRM Pereira","year":"2018","unstructured":"Pereira, P. R. M. et al. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat. Commun. 9, 5137 (2018).","journal-title":"Nat. Commun."},{"key":"10275_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","volume":"164","author":"R Marcotte","year":"2016","unstructured":"Marcotte, R. et al. Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance. Cell 164, 293\u2013309 (2016).","journal-title":"Cell"},{"key":"10275_CR45","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1091\/mbc.e12-04-0282","volume":"24","author":"K Cortese","year":"2013","unstructured":"Cortese, K. et al. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs\/lysosomal compartments. Mol. Biol. Cell 24, 129\u2013144 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"10275_CR46","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-09-3768","volume":"70","author":"C Marx","year":"2010","unstructured":"Marx, C., Held, J. M., Gibson, B. W. & Benz, C. C. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res. 70, 3709\u20133717 (2010).","journal-title":"Cancer Res."},{"key":"10275_CR47","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1021\/mp200641e","volume":"9","author":"RS Funk","year":"2012","unstructured":"Funk, R. S. & Krise, J. P. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol. Pharm. 9, 1384\u20131395 (2012).","journal-title":"Mol. Pharm."},{"key":"10275_CR48","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C Rios-Luci","year":"2017","unstructured":"Rios-Luci, C. et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 77, 4639\u20134651 (2017).","journal-title":"Cancer Res."},{"key":"10275_CR49","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman, C., Bagga, M., Kaur, A., Westermarck, J. & Abankwa, D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS ONE 9, e92444 (2014).","journal-title":"PLoS ONE"},{"key":"10275_CR50","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/0042-6822(73)90163-3","volume":"54","author":"FL Graham","year":"1973","unstructured":"Graham, F. L. & van der Eb, A. J. Transformation of rat cells by DNA of human adenovirus 5. Virology 54, 536\u2013539 (1973).","journal-title":"Virology"},{"key":"10275_CR51","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1101\/gr.6.10.986","volume":"6","author":"CA Heid","year":"1996","unstructured":"Heid, C. A., Stevens, J., Livak, K. J. & Williams, P. M. Real time quantitative PCR. Genome Res. 6, 986\u2013994 (1996).","journal-title":"Genome Res."},{"key":"10275_CR52","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1600-0854.2012.01327.x","volume":"13","author":"A Arjonen","year":"2012","unstructured":"Arjonen, A., Alanko, J., Veltel, S. & Ivaska, J. Distinct recycling of active and inactive beta1 integrins. Traffic 13, 610\u2013625 (2012).","journal-title":"Traffic"},{"key":"10275_CR53","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0960-9822(01)00442-0","volume":"11","author":"M Roberts","year":"2001","unstructured":"Roberts, M., Barry, S., Woods, A., van der Sluijs, P. & Norman, J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11, 1392\u20131402 (2001).","journal-title":"Curr. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10275-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10275-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10275-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T18:41:27Z","timestamp":1671216087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10275-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10275"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10275-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/299586","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"7 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.S. and H.J. own stocks of Sartar Therapeutics and are board members. H.J. has a co-appointment at Orion Pharma, and has received fees from Orion Pharma and Neutron Therapeutics Ltd. J.I., M.P., and P.S. have filed a patent application related to these findings. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2340"}}